Sülforafan ve doksorubisin kombinasyonunun In Vitro antikanser etkilerinin araştırılması

Cancer disease is a leading cause of death in the world, its incidence and mortality are on the rise. According to the Global Cancer Observatory (GLOBOCAN), there were approximately 19.3 million new cancer cases and nearly 10.0 million cancer deaths worldwide in 2020. This study was performed to determine the synergistic/cytotoxic effects of Doxorubicin which is an anthracycline chemotherapy drug and its combination with Sulforaphane an oily phytochemical isothiocyanate in 3T3, Caco-2, U2OS and HepG2 cells. For this, The MTT method was used to investigate the cytotoxic effects of single and combined applications of Doxorubicin and Sulforaphane in these cell lines, and CDI values were calculated in each cell line. The cytotoxic effects of Doxorubicin and Sulforaphane in 3T3, Caco-2, U2OS and HepG2 cells occur depending on concentration as shown in the MTT results. The CDI calculation results due to cell viability have determined that combined application of Doxorubicin with Sulforaphane has a synergistic effect on U2OS cells at a concentration of Dox 25+SFN 25 and DOX 25+SFN 50 (CDI < 1), while combined applications of Doxorubicin with Sulforaphane at different concentrations used in this study have antagonist effect on 3T3, Caco-2 and HepG2 (CDI > 1).